Equities analysts expect Xenon Pharmaceuticals Inc. (NASDAQ:XENE) to announce earnings per share (EPS) of ($0.48) for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Xenon Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.49) and the highest estimate coming in at ($0.47). Xenon Pharmaceuticals reported earnings of ($0.43) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 11.6%. The firm is scheduled to issue its next earnings report on Tuesday, May 8th.
According to Zacks, analysts expect that Xenon Pharmaceuticals will report full-year earnings of ($1.45) per share for the current financial year, with EPS estimates ranging from ($1.79) to ($1.21). For the next year, analysts expect that the business will post earnings of ($1.69) per share, with EPS estimates ranging from ($1.88) to ($1.49). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research analysts that cover Xenon Pharmaceuticals.
Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings results on Wednesday, March 7th. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.34). Xenon Pharmaceuticals had a negative net margin of 9,872.67% and a negative return on equity of 65.72%. The business had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $6.38 million.
NASDAQ XENE traded up $0.25 during trading hours on Thursday, reaching $5.25. 58,721 shares of the company’s stock traded hands, compared to its average volume of 71,162. Xenon Pharmaceuticals has a 52-week low of $2.10 and a 52-week high of $5.80. The stock has a market cap of $72.98, a P/E ratio of -3.05 and a beta of 0.75. The company has a debt-to-equity ratio of 0.17, a current ratio of 10.98 and a quick ratio of 10.99.
Institutional investors have recently modified their holdings of the business. Sabby Management LLC raised its holdings in Xenon Pharmaceuticals by 7.1% in the fourth quarter. Sabby Management LLC now owns 329,400 shares of the biopharmaceutical company’s stock worth $931,000 after buying an additional 21,800 shares during the last quarter. K2 Principal Fund L.P. raised its holdings in Xenon Pharmaceuticals by 33.5% in the fourth quarter. K2 Principal Fund L.P. now owns 219,543 shares of the biopharmaceutical company’s stock worth $620,000 after buying an additional 55,033 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in Xenon Pharmaceuticals by 59.2% in the fourth quarter. Renaissance Technologies LLC now owns 249,000 shares of the biopharmaceutical company’s stock worth $703,000 after buying an additional 92,600 shares during the last quarter. 64.62% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Xenon Pharmaceuticals Inc. (XENE) Expected to Post Earnings of -$0.48 Per Share” was posted by Dakota Financial News and is owned by of Dakota Financial News. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://dakotafinancialnews.com/2018/04/13/xenon-pharmaceuticals-inc-xene-expected-to-post-earnings-of-0-48-per-share.html.
About Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.